Suchergebnisse - "F0P408N6V4"

PubPharm (362)

1

Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelodysplastic syndromes : the HOVON89 trial

enthalten in: Leukemia | 2024

von van de Loosdrecht, A. | Cremers, E. | Alhan, C. | +37

2

Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation

enthalten in: Haematologica | 2024

von Epstein-Peterson, Z. | Drill, E. | Aypar, U. | +21

3

Combination of acalabrutinib with lenalidomide and rituximab in relapsed/refractory aggressive B-cell non-Hodgkin lymphoma : a single-arm phase II trial

enthalten in: Nature communications | 2024

von Park, C. | Lee, H. | Kang, K. | +16

4

Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma : An open label, phase 2 study

enthalten in: Cancer | 2024

von Gordon, M. | Feng, L. | Strati, P. | +20

5

A phase II study of interrupted and continuous dose lenalidomide in relapsed/refractory Hodgkin lymphoma

enthalten in: Haematologica | 2024

von Fehniger, T. | Watkins, M. | Ezenwajiaku, N. | +14

6

Polatuzumab vedotin plus rituximab and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma : a cohort of a multicentre, single-arm, phase 1b/2 study

enthalten in: The Lancet. Haematology | 2024

von Abrisqueta, P. | González-Barca, E. | Panizo, C. | +13

7

Belantamab mafodotin, lenalidomide, and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma : Analysis of belantamab mafodotin-associated ocular adverse events and their impact on daily functioning from the part 1 of a phase 1/2 study

enthalten in: American journal of hematology | 2024

von Gavriatopoulou, M. | Ntanasis-Stathopoulos, I. | Malandrakis, P. | +11

8

Tafasitamab for patients with relapsed or refractory diffuse large B-cell lymphoma : final 5-year efficacy and safety findings in the phase II L-MIND study

enthalten in: Haematologica | 2024

von Duell, J. | Abrisqueta, P. | Andre, M. | +14

9

Efficacy and safety of daratumumab with ixazomib and dexamethasone in lenalidomide-exposed patients after one prior line of therapy : Final results of the phase 2 study DARIA

enthalten in: American journal of hematology | 2024

von Terpos, E. | Ntanasis-Stathopoulos, I. | Gavriatopoulou, M. | +11

10

MRD-driven treatment with venetoclax-R2 in mantle cell lymphoma : the Nordic Lymphoma Group MCL7 VALERIA trial

enthalten in: Blood advances | 2024

von Jerkeman, M. | Kolstad, A. | Hutchings, M. | +12

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[37]